BioCardia, Inc. Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Jul 8, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, disclosure
TL;DR
BioCardia filed an 8-K on July 8, 2024, covering financial statements and disclosures.
AI Summary
On July 8, 2024, BioCardia, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and based in Sunnyvale, CA.
Why It Matters
This filing provides important updates and disclosures for investors regarding BioCardia, Inc.'s financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report detailing financial statements and disclosures, with no immediate indication of significant new risks.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- July 8, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by BioCardia, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on July 8, 2024.
What is BioCardia, Inc.'s state of incorporation?
BioCardia, Inc. is incorporated in Delaware.
What is BioCardia, Inc.'s business address?
BioCardia, Inc.'s business address is 320 Soquel Way, Sunnyvale, CA 94085.
What were some of BioCardia, Inc.'s former company names?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., Cardo Medical, Inc., and CLICKNSETTLE COM INC.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-07-08 07:00:39
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240706_8k.htm (8-K) — 27KB
- ex_695818.htm (EX-99.1) — 10KB
- 0001437749-24-022267.txt ( ) — 186KB
- bcda-20240708.xsd (EX-101.SCH) — 4KB
- bcda-20240708_def.xml (EX-101.DEF) — 13KB
- bcda-20240708_lab.xml (EX-101.LAB) — 17KB
- bcda-20240708_pre.xml (EX-101.PRE) — 13KB
- bcda20240706_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 1, 2024, CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. (the "Company") issued a press release announcing success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction led by CellProthera. The press release also announced plans to continue the relationship into Phase III. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated July 8, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: July 8, 2024